The Efficacy of Bisphosphonates for Prevention of Osteoporotic Fracture: An Update Meta-analysis

Ji-Hye Byun1,*, Sunmee Jang1,*, Sumin Lee1, Suyeon Park1, Hyun Koo Yoon2, Byung-Ho Yoon1,*, Yong-Chan Ha4,*,

1College of Pharmacy and Gachon Institute of Pharmaceutical Sciences, Gachon University, Incheon; 2Department of Internal Medicine, Cheil General Hospital & Women's Healthcare Center, Dankook University College of Medicine, Seoul; 3Department of Orthopaedic Surgery, Inje University College of Medicine, Seoul Paik Hospital, Seoul; 4Department of Orthopaedic Surgery, Chung-Ang University College of Medicine, Seoul, Korea

Background: The efficacy of bisphosphonates for osteoporotic fracture has been consistently reported in recent randomized controlled trials (RCTs) enrolling hundreds of patients. The objective of this study was to update knowledge on the efficacy of available bisphosphonates in the prevention of vertebral and non-vertebral fractures.

Methods: An approach “using systematic reviews” on PubMed and Cochrane Library was taken. Twenty-four RCTs investigating the effects of bisphosphonates for the prevention of osteoporotic fracture were included in final analysis. A pairwise meta-analysis was conducted with a random effects model. Subgroup analysis was performed according to the type of bisphosphonate.

Results: The use of bisphosphonate decrease the risk of overall osteoporotic fracture (odds ratio [OR] 0.62; \(P<0.001\)), vertebral fracture (OR 0.55; \(P<0.001\)) and non-vertebral fracture (OR 0.73; \(P<0.001\)). Subgroup analysis indicated that zoledronic acid showed the lowest risk reduction (OR 0.61; \(P<0.001\)) for overall osteoporotic fractures but no significance was observed for etidronate (OR 0.34; \(P=0.127\)).

Conclusions: This update meta-analysis re-confirmed that bisphosphonate use can effectively reduce the risk of osteoporotic fracture. However, there is a lack of evidence regarding etidronate for the prevention of osteoporotic fracture.

Key Words: Diphosphonates, Fractures bone, Meta-analysis as topic, Osteoporosis

INTRODUCTION

Osteoporotic fracture is recognized as a major social health problem.[1] Patients who sustain osteoporotic fractures have higher rates of morbidity and mortality. [2] Recently, several pharmacologic treatment options including antiresorptive or anabolic agents have been continuously developed.[3,4] However, bisphosphonates such as alendronate, risedronate, ibandronate and zoledronate are still the mainstay of anti-osteoporotic treatment.[5]

The efficacy of bisphosphonate in postmenopausal women has been thoroughly researched and reported in many clinical trials.[6-8] Moreover, a number of meta-analyses of bisphosphonates have been performed, but recently there have been adverse effects related reviews and relatively few reviews on the clinical impact of fracture prevention in the overall population.[9,10] To date, many clinical trials have been undertaken to elucidate the impact of bisphosphonate for osteo-
porotic fracture prevention.

Thus, we conducted an update meta-analysis to evaluate the efficacy of bisphosphonate regarding the prevention of osteoporotic fracture in patients with osteoporosis. The purpose of our update study was to determine the incidence of (1) overall osteoporotic fracture, (2) vertebral/non-vertebral fracture between intervention and placebo group.

METHODS

1. Literature search of previous systemic reviews

This search was conducted according to the updated preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) guidelines (Appendix S1). [11] First, a comprehensive search for systematic reviews or meta-analyses comparing outcomes between bisphosphonate and placebo in patients with osteoporosis on Cochrane Library (Cochrane Database of Systematic Review) was performed on November 13, 2016. The methodological quality of the included systematic reviews was independently assessed by the first two authors using the Assessment of Multiple Systematic Reviews (AMSTAR) tool. [12] Thereafter, we identified relevant randomized controlled trials (RCT) through the examination of reference lists from selected meta-analyses. [13-16]

2. Literature search for update clinical trials

We performed an additional updated searching of primary studies on PubMed-Medline and Cochrane Library search in November 2016 using key terms (bisphosphonate OR osteoporosis OR fracture). An overview of the search strategy and general characteristics about the four included systematic reviews are summarized in Appendix S2. Inclusion criteria were as follows: (1) study was a RCT, (2) patients were above 50 years old, and (3) articles that provided the rate of osteoporotic fracture. The intervention of at least one study group included the following bisphosphonates: alendronate, etidronate, ibandronate, risedronate, clodronate minodronate, pamidronate, tiludronate or zoledronic acid. We restricted our review to English and Korean studies, owing to translation difficulties and lack of resources for review. Basic science articles, comments, and letters were all excluded. When a published, updated study involving the same cohort of patients was identified, only the latest update was included in the analysis.

3. Outcome measure and data extraction

The primary outcome of interest was the rate of osteoporotic fracture including all fractures. Osteoporotic fractures were categorized into vertebral fractures and non-vertebral fractures. Additionally, we performed a subgroup analysis according to the type of bisphosphonate.

For each selected study, the following data were extracted and entered in a spread sheet by the two reviewers: the family name of the first author, the year of publication, enrollment period, study design, number of patients, number of osteoporotic fracture, mean age at the time of intervention, and the duration of follow-up.

4. Quality assessment and publication bias

Two of the authors (BJH, YBH) independently evaluated the quality of all the studies, using the criteria described in the Cochrane Handbook for Systematic Reviews of Interventions. The criteria included the following 7 items: (1) random sequence generation (2) allocation concealment (3) blinding of participants and personnel (4) blinding of outcome data (5) incomplete outcome data addressed (6) selective reporting (7) other biases. We assessed publication bias with Begg’s funnel plot and Egger’s test.

5. Statistical analysis

For each study, we calculated the odds ratio (OR) with a 95% confidence interval (CI) by using crude 2×2 tables, whenever possible, from the comparative studies. [17] The Mantel–Haenszel method was used to calculate the OR due to zero values in any cell count in a table. [18] Heterogeneity between comparable studies was tested with the chi-square and Higgins I² test. P-value of less than 0.1 or an I² value higher than 50% meant significant heterogeneity and a random-effects model should be applied. There was significant heterogeneity between the included studies (P=0.001). Thus, we reported the data from a randomized-effect. All analyses were performed using STATA version 14.0 software (Stata Corporation, College Station, TX, USA).

This study was exempted from institutional review board review since it did not involve any human subjects.
RESULTS

1. Description of selected trials

A primary search of databases yielded 2,755 records and a total of 24 studies were included in the final systematic review. From the initial searches, studies selected for final inclusion or exclusion are displayed in the flowchart (Fig. 1). Twenty-four randomized placebo controlled trials investigating the effects of alendronate (6 studies), risedronate (5 studies), etidronate (4 studies), zoledronic acid (4 studies), clodronate (2 studies), ibandronate (1 study), minodronate (1 study), and pamidronate (1 study) were identified with a systematic literature search.[6-8,19-39] The characteristics of studies included are summarized in Table 1. A final total of 39,197 patients were included in our meta-analysis: 21,335 patients in the bisphosphonate group and 17,862 patients in the placebo group.

2. The overall rate of osteoporotic fracture

The overall rate of osteoporotic fracture was 7.7% (3,036/39,197): 5.9% (1,268/21,355) in the bisphosphonate group and 9.9% (1,768/17,862) in the placebo group. The overall rate of vertebral fracture was 5.9% (446/7,585) in the bisphosphonate group and 10.3% (741/7,190) in the placebo group. The overall rate of non-vertebral fracture was 6.0% (822/13,750) in the bisphosphonate group and 9.6% (1,027/10,672) in the placebo group.

3. Efficacy of bisphosphonate for osteoporotic fracture risk reduction

In the random effects model for all studies, the use of bisphosphonate was associated with a decreased risk of osteoporotic fracture (OR 0.62; 95% CI 0.54 to 0.71 $P<0.001$). In vertebral fracture, the use of bisphosphonate was associated with a decreased risk of osteoporotic fracture (OR 0.55; 95% CI 0.44 to 0.69 $P<0.001$) and non-vertebral fracture (OR 0.73; 95% CI 0.67 to 0.81 $P<0.001$) (Fig. 2). In the subgroup analysis, zoledronic acid showed the lowest OR with significance for overall osteoporotic fractures (Table 2).

4. Quality assessment and publication bias

In terms of the methodological quality, subjects were randomized by established allocation sequence, and investigators and research assistants were all blind to allocation. However, it is unclear whether the included trials met all the quality assessment criteria (Fig. 3). The Begg’s funnel plot was symmetrical, and $P$-value for bias was 0.192 in the Egger’s test for the included trials (Fig. 4).

DISCUSSION

One potential approach to enhance the management of osteoporosis is drug treatment that decreases osteoclastic activity.[40] Bisphosphonates are widely used as first-line drug therapy for preventing osteoporotic fracture and their
density-increasing effects in postmenopausal women.[41]

Our update review included quality-proven 24 RCTs and the observed OR was 0.62 for total osteoporotic fracture and 0.55 for vertebral fracture. The effect of bisphosphonates on anti-fracture was similar to that obtained in a previous meta-analysis reporting beneficial effects of bisphosphonates in postmenopausal women. Relative risk reduction in vertebral fractures ranged from 0.55 to 0.61.[13-16] However, etidronate use did not show significant risk reduction for non-vertebral fractures.[14] This finding was similarly observed in our analysis from four RCTs (Table 2).

The efficacy of bisphosphonates varied between the included studies. A previous network meta-analysis demonstrated that zoledronic acid was most effective for reducing vertebral fractures.[41] Our study also noted the lowest
density-increasing effects in postmenopausal women.[41]

Table 1. Characteristics of included individual studies

| References                  | Treatment duration | Intervention      | Outcome | Intervention/Placebo | Patients enrolled | No. of osteoporotic fracture |
|-----------------------------|--------------------|-------------------|---------|----------------------|-------------------|-----------------------------|
| Storm et al. 1990 [38]      | 3 years            | Etidronate 400 mg | VF      | VF & NVF             | 100/100           | 6/54                        |
| Reid et al. 1994 [37]       | 2 years            | Pamidronate (150 mg/day) | VF      | VF                   | 26/22             | 7/10                        |
| Liberman et al. 1995 [28]   | 2 years            | Alendronate 5, 10, 20 mg | VF      | VF                   | 526/355           | 17/22                       |
| Black et al. 1996 [19]      | 2 years            | Alendronate 5, 10 mg | VF      | VF                   | 975/967           | 78/145                      |
| Clemmesen et al. 1997 [23]  | 2 years            | Risedronate 2.5 mg | VF      | VF                   | 62/31             | 28/20                       |
| Herd et al. 1997 [26]       | 2 years            | Etidronate        | VF      | VF                   | 75/77             | 0/0                         |
| Meunier et al. 1997 [33]    | 2 years            | Etidronate        | VF & NVF| VF                   | 54/55             | 0/0                         |
| Pouilles et al. 1997 [35]   | 2 years            | Etidronate        | VF      | VF                   | 54/55             | 0/0                         |
| Cummings et al. 1998 [24]   | 2 years            | Alendronate 5, 10 mg | VF      | VF & NVF             | 696/678           | 61/93                       |
| Hosking et al. 1998 [27]    | 2 years            | Alendronate       | VF & NVF| VF                   | 498/468           | 22/14                       |
| Harris et al. 1998 [25]     | 3 years            | Risedronate 2.5, 5 mg | VF & NVF| VF                   | 812/812           | 33/33                       |
| Onwoll et al. 2000 [34]     | 2 years            | Alendronate 10 mg | VF      | VF                   | 146/95            | 1/7                         |
| Reginster et al. 2000 [36]  | 2 years            | Risedronate 2.5, 5 mg | VF & NVF| VF                   | 344/346           | 33/33                       |
| McClung et al. 2001 [32]    | 2 years            | Risedronate 2.5, 5 mg | VF      | VF                   | 61/134            | 137/95                      |
| McCloskey et al. 2004 [31]  | 3 years            | Clodronate 800 mg | VF      | VF                   | 260/270           | 33/63                       |
| Chesnutt et al. 2004 [22]   | 3 years            | Ibandronate 2.5 mg | VF      | VF                   | 787/760           | 37/73                       |
| McCloskey et al. 2007 [39]  | 3 years            | Clodronate 800 mg | VF      | VF                   | 2,779/2,785       | 264/337                     |
| Lyles et al. 2007 [29]      | 2 years            | Zoledronic acid 5 mg | VF & NVF| VF                   | 1,065/1,062       | 92/139                      |
| Boonen et al. 2009 [20]     | 2 years            | Risedronate 35 mg | VF      | VF                   | 191/93            | 59/28                       |
| Matsumoto et al. 2009 [30]  | 2 years            | Minodronate 1 mg  | VF      | VF                   | 246/219           | 4/17                        |
| Boonen et al. 2012 [21]     | 2 years            | Zoledronic acid 5 mg | VF      | VF                   | 555/574           | 9/28                        |
| Chao et al. 2013 [7]        | 2 years            | Zoledronic acid 5 mg | VF & NVF| VF                   | 327/333           | 21/35                       |
| Bai et al. 2013 [8]         | 2 years            | Zoledronic acid 5 mg | NVF     | NVF                  | 242/241           | 19/32                       |
| van de Giind et al. 2016 [6]| 2 years            | Alendronate       | VF & NVF| VF                   | 1,841/1,817       | 215/296                     |

VF, vertebral fracture; NVF, non-vertebral fracture.

Table 2. The efficacy of bisphosphonate for prevention of osteoporotic fracture by subgroup analysis

| Type of bisphosphonate | No. of trials | Odds ratio (95% CI) | P-value |
|------------------------|---------------|---------------------|---------|
| Alendronate            | 6             | 0.64 (0.48-0.84)    | 0.002   |
| Risedronate            | 5             | 0.74 (0.63-0.85)    | <0.001  |
| Etidronate             | 4             | 0.34 (0.08-1.36)    | 0.127   |
| Zoledronic acid        | 4             | 0.61 (0.49-0.76)    | <0.001  |
| Clodronate             | 2             | 0.69 (0.49-0.98)    | 0.035   |

efficacy is well-established. The objective of the current study was to synthesize updated evidence of bisphosphonates in the prevention of vertebral and non-vertebral fractures among patients with osteoporosis. A previous meta-analysis which included 8 RCTs reported that the use of bisphosphonates may result in anti-fracture and bone mineral
Fig. 2. (A) The forest plot of overall osteoporotic fracture reductions relative to placebo by bisphosphonate treatment. The forest plot of odds ratio for (B) vertebral fracture. (Continued to the next page)
Fig. 2. (Continued) (C) non-vertebral fracture. OR, odds ratio; CI, confidence interval.

Fig. 3. The funnel plot shows publication bias for osteoporotic fracture related to the use of bisphosphonate. There was symmetry, suggesting that there was no significant publication bias in the twenty-four studies.

OR in zoledronic acid. Improved compliance and poor gastrointestinal absorption of oral bisphosphonates are suggested as a possible explanation. Although there is a difference of efficacy between different types of bisphosphonate, the efficacy of bisphosphonate was predominantly dependent on the compliance to bisphosphonate.[42]

This study has some limitations. First, the current analysis did not involve evidence on quality of life or survival. Secondly, the potential adverse effects of bisphosphonates were not evaluated in this study. Third, hip fractures which are significantly associated with morbidity and mortality were not analyzed separately.

In conclusion, this update meta-analysis re-confirmed
the efficacy of bisphosphonate in patients with osteoporosis. In terms of their anti-osteoporotic fracture efficacy, bisphosphonates except etidronate still demonstrate its effectiveness.

ACKNOWLEDGEMENT

This research was supported by a grant of the Korea Health Technology R & D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Korea (grant number : HI13C1522 and HC15C1189).

Sponsor's Role: The funding organizations had no role in the design, methods, analysis, preparation, or approval of the paper. The views expressed in this publication are those of the authors and not necessarily those of the KHIDI.

REFERENCES

1. Svensson HK, Olofsson EH, Karlsson J, et al. A painful, never ending story: older women’s experiences of living with an osteoporotic vertebral compression fracture. Osteoporos Int 2016;27:1729-36.
2. Park C, Jang S, Lee A, et al. Incidence and mortality after proximal humerus fractures over 50 years of age in South Korea: national claim data from 2008 to 2012. J Bone Metab 2015;22:17-21.
3. Im GL, Lee SH. Effect of teriparatide on healing of atypical femoral fractures: a systemic review. J Bone Metab 2015; 22:183-8.
4. Choi NK, Solomon DH, Tsacogianis TN, et al. Comparative safety and effectiveness of denosumab versus zoledronic acid in patients with osteoporosis: a cohort study. J Bone Miner Res 2016.
5. Bilezikian JP. Efficacy of bisphosphonates in reducing fracture risk in postmenopausal osteoporosis. Am J Med 2009; 122:514-21.
6. van de Glind EM, Willems HC, Eslami S, et al. Estimating the time to benefit for preventive drugs with the statistical process control method: an example with alendronate. Drugs Aging 2016;33:347-53.
7. Chao M, Hua Q, Yingfeng Z, et al. Study on the role of zoledronic acid in treatment of postmenopausal osteoporosis women. Pak J Med Sci 2013;29:1381-4.
8. Bai H, Jing D, Guo A, et al. Randomized controlled trial of zoledronic acid for treatment of osteoporosis in women. J Int Med Res 2013;41:697-704.
9. Ou YJ, Chiu HF, Wong YH, et al. Bisphosphonate use and the risk of endometrial cancer: a meta-analysis of observational studies. Pharmacoepidemiol Drug Saf 2016;25: 1107-15.
10. Wang J, Yao M, Xu JH, et al. Bisphosphonates for prevention of osteopenia in kidney-transplant recipients: a systematic review of randomized controlled trials. Osteoporos Int 2016;27:1683-90.
11. Shamseer L, Moher D, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ 2015; 349:g7647.
12. Shea BJ, Grimshaw JM, Wells GA, et al. Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews. BMC Med Res Methodol 2007;7:10.
13. Wells G, Cranney A, Peterson J, et al. Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev 2008:Cd004523.
14. Wells GA, Cranney A, Peterson J, et al. Etidronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev 2008:Cd003376.
15. Wells GA, Cranney A, Peterson J, et al. Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev 2008:Cd001155.
16. Zhou J, Wang T, Zhao X, et al. Comparative efficacy of bisphosphonates to prevent fracture in men with osteoporosis: a systematic review with network meta-analyses. Rheumatol Ther 2016;3:117-28.
17. Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions version 5.0.0. London, UK: The Cochrane Collaboration; 2008.
18. Borenstein M, Hedges LV, Higgins JPT, et al. Introduction to meta-analysis. West Sussex, UK: John Wiley & Sons; 2009.
19. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996;348:1535-41.
20. Boonen S, Orwoll ES, Wenderoth D, et al. Once-weekly risedronate in men with osteoporosis: results of a 2-year, pla-
21. Boonen S, Reginster JY, Kaufman JM, et al. Fracture risk and zoledronic acid therapy in men with osteoporosis. N Engl J Med 2012;367:1714-23.
22. Chesnut CH, 3rd, Skag A, Christiansen C, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004;19:1241-9.
23. Clemmesen B, Ravn P, Zegels B, et al. A 2-year phase II study with 1-year of follow-up of risedronate (NE-58095) in postmenopausal osteoporosis. Osteoporos Int 1997;7:488-95.
24. Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998;280:2077-82.
25. Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. N Engl J Med 1999;322:1344-52.
26. Herd RJ, Balena R, Blake GM, et al. The prevention of early postmenopausal bone loss by cyclical etidronate therapy: a 2-year, double-blind, placebo-controlled study. Am J Med 1997;103:92-9.
27. Hosking D, Chilvers CE, Christiansen C, et al. Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early Postmenopausal Intervention Cohort Study Group. N Engl J Med 1998;338:485-92.
28. Liberman UA, Weiss SR, Bröll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. J Bone Miner Res 1995;33:1437-43.
29. Lyles KW, Colón-Emeric CS, Magaziner JS, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 2007;357:1799-809.
30. Matsumoto T, Hagino H, Shiraki M, et al. Effect of daily oral minodronate on vertebral fractures in Japanese postmenopausal women with established osteoporosis: a randomized placebo-controlled double-blind study. Osteoporos Int 2009;20:1429-37.
31. McClung MR, Geusens P, Miller PD, et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 2001;344:333-40.
32. Meunier PJ, Confavreux E, Tupinon I, et al. Prevention of early postmenopausal bone loss with cyclical etidronate therapy (a double-blind, placebo-controlled study and 1-year follow-up). J Clin Endocrinol Metab 1997;82:2784-91.
33. Pouilles JM, Tremolieres F, Roux C, et al. Effects of cyclical etidronate therapy on bone loss in early postmenopausal women who are not undergoing hormonal replacement therapy. Osteoporos Int 1997;7:213-8.
34. Registry J, Minne HW, Sorensen OH, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. Osteoporos Int 2000;11:83-91.
35. Reid IR, Wattie DJ, Evans MC, et al. Continuous therapy with pamidronate, a potent bisphosphonate, in postmenopausal osteoporosis. J Clin Endocrinol Metab 1994;79:1595-9.
36. Storm T, Thamsborg G, Steiniche T, et al. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N Engl J Med 1990;322:1265-71.
37. McClung EV, Beneton M, Charlesworth D, et al. Clodronate reduces the incidence of fractures in community-dwelling elderly women unselected for osteoporosis: results of a double-blind, placebo-controlled randomized study. J Bone Miner Res 2007;22:135-41.
38. Jansen JP, Bergman GJ, Huels J, et al. The efficacy of bisphosphonates in the prevention of vertebral, hip, and nonvertebral-nonhip fractures in osteoporosis: a network meta-analysis. Semin Arthritis Rheum 2011;40:275-84.e1-2.
39. Lee YJ, Park CH, Lee YK, et al. Which bisphosphonate? It’s the compliance!: Decision analysis. J Bone Metab 2016;23:79-83.
### Appendix 1. The updated checklist consists of 17-items intended to facilitate the preparation and reporting of a robust protocol for the meta-analysis and systematic review

| Section and topic | Item no. | Checklist Item | Page no. |
|-------------------|----------|----------------|----------|
| ADMINISTRATIVE INFORMATION | | | |
| Title: Identification | 1a | Identify the report as a protocol of a systematic review | 1 |
| Update | 1b | If the protocol is for an update of a previous systematic review, identify as such | 1 |
| Registration | 2 | If registered, provide the name of the registry (such as PROSPERO) and registration number | Not applicable |
| Authors: Contact | 3a | Provide name, institutional affiliation, e-mail address of all protocol authors; provide physical mailing address of corresponding author | 1 |
| Contributions | 3b | Describe contributions of protocol authors and identify the guarantor of the review | 1 |
| Amendments | 4 | If the protocol represents an amendment of a previously completed or published protocol, identify as such and list changes; otherwise, state plan for documenting important protocol amendments | Not applicable |
| Support: Sources | 5a | Indicate sources of financial or other support for the review | 7 |
| Sponsor | 5b | Provide name for the review funder and/or sponsor | 7 |
| Role of sponsor or funder | 5c | Describe roles of funder(s), sponsor(s), and/or institution(s), if any, in developing the protocol | 7 |
| INTRODUCTION | | | |
| Rationale | 6 | Describe the rationale for the review in the context of what is already known | 2 |
| Objectives | 7 | Provide an explicit statement of the question(s) the review will address with reference to participants, interventions, comparators, and outcomes (PICO) | 2 |
| METHODS | | | |
| Eligibility criteria | 8 | Specify the study characteristics (such as PICO, study design, setting, time frame) and report characteristics (such as years considered, language, publication status) to be used as criteria for eligibility for the review | 2 |
| Information sources | 9 | Describe all intended information sources (such as electronic databases, contact with study authors, trial registers or other grey literature sources) with planned dates of coverage | 2 |
| Search strategy | 10 | Present draft of search strategy to be used for at least one electronic database, including planned limits, such that it could be repeated | 2 |
| Study records: Data management | 11a | Describe the mechanism(s) that will be used to manage records and data throughout the review | 2 |
| Selection process | 11b | State the process that will be used for selecting studies (such as two independent reviewers) through each phase of the review (that is, screening, eligibility and inclusion in meta-analysis) | 2 |
| Data collection process | 11c | Describe planned method of extracting data from reports (such as piloting forms, done independently, in duplicate), any processes for obtaining and confirming data from investigators | 2 |
| Data items | 12 | List and define all variables for which data will be sought (such as PICO items, funding sources), any pre-planned data assumptions and simplifications | 2 |
| Outcomes and prioritization | 13 | List and define all outcomes for which data will be sought, including prioritization of main and additional outcomes, with rationale | 2 |
| Risk of bias in individual studies | 14 | Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the outcome or study level, or both; state how this information will be used in data synthesis | 3 |
| Data synthesis | 15a | Describe criteria under which study data will be quantitatively synthesised | 3 |
| 15b | If data are appropriate for quantitative synthesis, describe planned summary measures, methods of handling data and methods of combining data from studies, including any planned exploration of consistency (such as I², Kendall’s τ) | 3-6 |
| 15c | Describe any proposed additional analyses (such as sensitivity or subgroup analyses, meta-regression) | 3-6 |
| 15d | If quantitative synthesis is not appropriate, describe the type of summary planned | Not applicable |
| Meta-bias(es) | 16 | Specify any planned assessment of meta-bias(es) (such as publication bias across studies, selective reporting within studies) | Fig. 3 |
| Confidence in cumulative evidence | 17 | Describe how the strength of the body of evidence will be assessed (such as GRADE) | 2-3 |
Appendix 2. The search strategy that details the selection process of relevant clinical studies

Queries

I. Systemic review searching

1. Patients: Osteoporosis (T-score ≤ -2.5)
2. Intervention: Bisphosphonates (Alendronate, Ibandronate, Risedronate, Zoledronate, Etidronate, Clodronate, Minodronate, Pamidronate, Tiludronate) treatment
3. Comparator: Non-treatment
4. Outcomes: The incidence of osteoporotic fracture
5. Study design: Review or meta-analysis

Cochrane Library (November 20, 2016) - Filters: Cochrane Reviews all

| Queries            | Search |
|--------------------|--------|
| #1 Osteoporosis    | 497    |
| #2 Bisphosphonate  | 64     |
| #3 Fracture        | 769    |
| #4 Search (#1 AND #2 AND #3) | 44     |

After primary review, a total of 4 meta-analyses were included

| References   | No. of included patients | No. of included studies | AMSTAR |
|--------------|--------------------------|-------------------------|--------|
| 1 Zhou (2016)| 16,542                   | 36 RCTs                 | Yes: 7 No: 4 |
| 2 Wells (2008)| 12,068                  | 11 RCTs                 | Yes: 7 No: 4 |
| 3 Wells (2008)| 14,049                  | 7 RCTs                  | Yes: 7 No: 4 |
| 4 Wells (2008)| 1,248                   | 11 RCTs                 | Yes: 7 No: 4 |
II. Update searching of randomized controlled trials

1. Patients: Osteoporosis (T-score ≤ -2.5)
2. Intervention: Bisphosphonates [Alendronate, Ibandronate, Risedronate, Zoledronate, Etidronate, Clodronate, Minodronate, Pamidronate, Tiludronate] treatment
3. Comparator: Non-treatment
4. Outcomes: The incidence of osteoporotic fracture
5. Study design: Randomized controlled trial

PubMed (November 20, 2016)

| Queries                                                                 | Search |
|-------------------------------------------------------------------------|--------|
| #1 *alendronate*[tw]                                                     | 4,623  |
| #2 alendronate[MeSH]                                                    | 3,222  |
| #3 *Aminohydroxybutane Bisphosphonate*[tw] OR *Bisphosphonate, Aminohydroxybutane*[tw] OR *4-Amino-1-Hydroxybutyridenedi-1,1-Bisphosphonate*[tw] OR *4 Amino 1 Hydroxybutyridenedi-1,1 Bisphosphonate*[tw] OR *Alendronate Sodium*[tw] OR *Sodium, Alendronate*[tw] OR *Alendronate Monosodium Salt, Trihydrate*[tw] OR *Fosamax*[tw] OR *MK-217*[tw] OR *MK 217*[tw] OR *MK217*[tw] | 323    |
| #4 search (#1 OR #2 OR #3)                                              | 4,642  |
| #5 risedronate[MeSH]                                                   | 1,070  |
| #6 *risedronate*[tw]                                                    | 1,739  |
| #7 *Sodium, Risedronate*[tw] OR *2-(3-pyridinyl)-1-hydroxyethylidenedi-bisphosphonate*[tw] OR *1-Hydroxy-2-(3-pyridyl)ethylidenedi-phosphonate*[tw] OR *2-(3-pyridinyl)-1-hydroxyethylidenedi-bisphosphonate*[tw] OR *Risedronic Acid, Monosodium Sal*[tw] OR *Risedronate*[tw] OR *Bisphosphate Risedronate Sodium*[tw] OR *Risedronate Sodium, Bisphosphate*[tw] OR *Sodium, Bisphosphate Risedronate*[tw] OR *Risedronic Acid*[tw] OR *Acid, Risedronic*[tw] OR *Actonel*[tw] OR *Atelvia*[tw] | 1,762  |
| #8 search (#5 OR #6 OR #7)                                              | 1,762  |
| #9 ibandronate[MeSH]                                                   | -      |
| #10 *ibandronate*[tw]                                                   | 902    |
| #11 *Bondronat*[tw] OR *Boniva*[tw] OR *ibandronic acid, sodium salt, monohydrate*[tw] OR *RPR 102289A*[tw] OR *RPR-102289A*[tw] OR *Boniva*[tw] OR *BM 21.0955*[tw] OR *BM-21.0955*[tw] OR *BM 210955*[tw] OR *BM 210955*[tw] OR *ibandronate*[tw] OR *(1-hydroxy-3-(methylpentylamino)propylidene)bisphosphonate*[tw] OR *(1-hydroxy-3-(methylpentylamino)propylidene)bisphosphonate*[tw] | 919    |
| #12 search (#9 OR #10 OR #11)                                           | 919    |
| #13 *zoledronic acid*[tw]                                               | 3,739  |
| #14 zoledronic acid[MeSH]                                               | 81     |
| #15 *(2-imidazol-1-yl)-1-hydroxyethylidene-1,1-bisphosphonic acid*[tw] OR *zoledronate*[tw] OR *Zometra*[tw] OR *Novartis brand of zoledronic acid*[tw] OR *CGP 42446A*[tw] OR *CGP-42446*[tw] OR *CGP-42'446*[tw] OR *CGP 42'446*[tw] | 1,038  |
| #16 search (#13 OR #14 OR #15)                                          | 4,131  |
| #17 *clodronate*[tw]                                                   | 1,695  |
| #18 clodronate[MeSH]                                                   | 1,505  |
| #19 *Acid, Clodronic*[tw] OR *Dichloromethane Diphosphonate*[tw] OR *Diphosphonate, Dichloromethane*[tw] OR *Dichloromethylenebisphosphonate*[tw] OR *Dichloromethanediphosphonic Acid*[tw] OR *Acid, Dichloromethanediphosphonic*[tw] OR *Dichloromethylene Biphosphonate*[tw] OR *Biphosphonate, Dichloromethylene*[tw] OR *Dichloromethylene Diphosphonate*[tw] OR *Diphosphonate, Dichloromethylene*[tw] OR *C2ZMDP*[tw] OR *Dichloromethanediphosphonic Acid*[tw] OR *Clodronate*[tw] OR *Clodronate Disodium*[tw] OR *Disodium, Clodronate*[tw] OR *Clodronate Sodium*[tw] OR *Sodium, Clodronate*[tw] OR *Bonefos*[tw] OR *pentoxylline-tocopherol-clodronate combination*[tw] OR *Pentoclo*[tw] | 2,057  |
| #20 search (#17 OR #18 OR #19)                                          | 2,393  |
| #21 *etidronate*[tw]                                                   | 1,231  |
| #22 etidronate[MeSH]                                                   | 2,723  |

(Continued to the next page)
### Queries

| #23 | "Hydroxyethylidene Diphosphonic Acid"[tw] OR "Diphosphonic Acid, Hydroxyethylidene"[tw] OR "[1-hydroxyethylene]diphosphonic acid"[tw] OR "Didronel"[tw] OR "Xidifon"[tw] OR "Kydiphone"[tw] OR "Kydiphon"[tw] OR "Etidronate Disodium"[tw] OR "Phosphonic acid, (1-hydroxyethylidene)bis-, disodium salt"[tw] OR "Disodium Etidronate"[tw] OR "Etidronate, Disodium"[tw] OR "Disodium 1-Hydroxyethylenediphosphonate"[tw] OR "1-Hydroxyethylenediphosphonate, Disodium"[tw] OR "Diphosphonate, Disodium 1-Hydroxyethylene"[tw] OR "Disodium 1 Hydroxyethylenediphosphonate"[tw] OR "HEDSPA"[tw] OR "Sodium Etidronate"[tw] OR "Etidronate, Sodium"[tw] OR "Etidronate, Tetrapotassium Salt"[tw] OR "Salt Etidronate, Tetrapotassium"[tw] OR "Tetrapotassium Salt Etidronate"[tw] OR "[1-hydroxyethylene]diphosphonic acid, Tetrapotassium Salt"[tw] OR "Dicalcium Etidronate"[tw] OR "Etidronate, Dicalcium"[tw] OR "Dicalcium EHDP"[tw] OR "EHDP, Dicalcium"[tw] OR "Etidronate"[tw] OR "1-Hydroxyethane-1,1-Diphosphonate"[tw] OR "1 Hydroxyethane 1,1 Diphosphonate"[tw] OR "1-Hydroxyethylidene-1,1-Bisphosphonate"[tw] OR "1 Hydroxyethylidene 1,1 Bisphosphonate"[tw] OR "Hydroxyethanediphosphonate"[tw] OR "Ethanehydroxydiphosphonate"[tw] OR "Ethanehydroxyphosphate"[tw] OR "HEDP"[tw] OR "1,1-hydroxyethylenediphosphonate"[tw] OR "1,1 hydroxyethylenediphosphonate"[tw] OR "EHDP"
| Search | 1,074 |

| #24 | search (#21 OR #22 OR #23) | 3,403 |

| #26 | "YM529"[tw] OR "ON0-5920"[tw] OR "YM-529"[tw] OR "Phosphonic acid, (1-hydroxy-2-imidazo(1,2-a)pyridin-3-ylethylidene)bis"[tw] OR "YH 529"[tw] OR "YH529"[tw] OR "YH-529"[tw] OR "[1-hydroxy-2-(imidazo(1,2-a)-pyridin-3-yl)ethylidene]bisphosphonic acid monohydrate"[tw] OR "minodronate"[tw] OR "minodronic acid hydrate"[tw] OR "1-hydroxy-2-(imidazo(1,2-a)pyridin-3-yl)ethane-1,1-bisphosphonic acid monohydrate"[tw]
| Search | 0 |

| #27 | minodronate[MeSH] | 0 |

| #29 | "pamidronate"[tw] | 2,861 |

| #31 | "3-amino-1-hydroxypropylidene)-1,1-bisphosphonate"[tw] OR "1-hydroxy-3-aminopropane-1,1-diphosphonic acid"[tw] OR "APD"[tw] OR "AHPBP"[tw] OR "aminohydroxypropylidene diphosphonate"[tw] OR "aminopropanehydroxydiphosphonate"[tw] OR "aminopropanehydroxydiphosphonate"[tw] OR "amidronate"[tw] OR "[3-amino-1-hydroxypropylidene)-1,1-bisphosphonate"[tw] OR "[aminopropanehydroxydiphosphonate"[tw] OR "pamidronate monosodium"[tw] OR "pamidronate disodium"[tw] OR "Aredia"[tw] OR "Novartis brand of pamidronate disodium salt"[tw] OR "pamidronate calcium"[tw]
| Search | 4,508 |

| #32 | search (#29 OR #30 OR #31) | 6,965 |

| #34 | "tiuludronate"[tw] | 133 |

| #35 | "(4-chlorophenyl)thiomethylene bisphosphonic acid"[tw] OR "Cl2SMBP"[tw] OR "tiludronate"[tw] OR "(chloro-4-phenyl)thiomethylene bisphosphonate"[tw] OR "(chloro-4-phenyl)thiomethylene bisphosphonate"[tw] OR "tiludronate disodium"[tw] OR "Skelid"[tw]
| Search | 137 |

| #36 | search (#33 OR #34 OR #35) | 137 |

| #37 | osteoporosis[tw] | 7,1974 |

| #38 | "osteoporosis"[MeSH] | 49,047 |

| #39 | "Osteoporesis"[tw] OR "Osteoporosis, Post-Traumatic"[tw] OR "Osteoporosis, Post Traumatic"[tw] OR "Post-Traumatic Osteoporoses"[tw] OR "Post-Traumatic Osteoporosis"[tw] OR "Osteoporosis, Senile"[tw] OR "Osteoporesis, Senile"[tw] OR "Osteoporesis, Senile Osteoporesis"[tw] OR "Senile Osteoporosis"[tw] OR "Osteoporosis, Involutional"[tw] OR "Osteoporosis, Age-Related"[tw] OR "Osteoporosis, Age Related"[tw] OR "Bone Loss, Age-Related"[tw] OR "Age-Related Bone Loss"[tw] OR "Age-Related Bone Losses"[tw] OR "Bone Loss, Age Related"[tw] OR "Bone Loss, Age Related"[tw] OR "Age-Related Osteoporosis"[tw] OR "Age Related Osteoporosis"[tw] OR "Age-Related Osteoporesis"[tw] OR "Osteoporoses, Age-Related"
| Search | 1,220 |

| #40 | search (#37 OR #38 OR #39) | 72,232 |

| #41 | "fracture"[tw] | 166,072 |

| #42 | fracture[MeSH] | 160,391 |

| #43 | "Broken Bones"[tw] OR "Bone, Broken"[tw] OR "Bones, Broken"[tw] OR "Broken Bone"[tw] OR "Bone Fractures"[tw] OR "Bone Fracture"[tw] OR "Fracture, Bone"[tw]
| Search | 63,905 |

| #44 | search (#41 OR #42 OR #43) | 228,415 |

| #45 | search (#4 OR #6 OR #12 OR #16 OR #20 OR #24 OR #28 OR #32 OR #36) | 12,670 |

| #46 | search (#40 AND #44 AND #45) | 2,703 |

| #47 | Search Filters: Clinical Trial; Full-text; Publication dates From 2014/01/01 to 2016/11/20; English, Korean; |
| Search | 36 |
Cochrane Library (November 20, 2016) – 56 articles

| Queries | Search |
|---------|--------|
| #1 alendronate | 1,097 |
| #2 “Aminohydroxybutane Bisphosphonate” OR “Bisphosphonate, Aminohydroxybutane” OR “4-Amino-1-Hydroxybutylidene 1,1-Biphosphonate” OR “4 Amino 1 Hydroxybutylidene 1,1 biphosphonate” OR “Alendronate Sodium” OR “Sodium, Alendronate” OR “Alendronate Monosodium Salt, Trihydrate” OR “Fosamax” OR “MK-217” OR “MK 217” OR “MK217” | 101 |
| #3 search (#1 OR #2) | 1,098 |
| #4 risedronate | 481 |
| #5 “Sodium, Risedronate” OR “2-(3-pyridinyl)-1-hydroxyethylidene-bisphosphonate” OR “1-Hydroxy-2-(3-pyridyl)ethylidene diphosphonate” OR “2-(3-pyridinyl)-1-hydroxyethylidenebisphosphonate” OR “Risedronic Acid, Monosodium Salt” OR “Risedronate” OR “Biphosphonate Risedronate Sodium” OR “Risedronate Sodium, Bisphosphate” OR “Sodium, Bisphosphate Risedronate” OR “Risedronic Acid” OR “Acid, Risedronic” OR “Actonel” OR “Atelvia” | 526 |
| #6 search (#4 OR #5) | 526 |
| #7 ibandronate | 312 |
| #8 “Bondronat” OR “Bonviva” OR “ibandronic acid, sodium salt, monohydrate” OR “RPR 102289A” OR “RPR-102289A” OR “Boniva” OR “BM 21.0955” OR “BM-21.0955” OR “BM-210955” OR “BM 210955” OR “ibandronate” OR “(1-hydroxy-3-(methylpentylamino)propylidene)bisphosphonate” | 314 |
| #9 search (#7 OR #8) | 314 |
| #10 search (#3 OR #6 OR #9) | 1678 |
| #11 MeSH descriptor: [Osteoporosis] explode all trees | 3,468 |
| #12 MeSH descriptor: [Bone, disease, Metabolic] this term only (SINGLE MESH TERM) | 312 |
| #13 MeSH descriptor: [Bone density, Metabolic] this term only | 4,306 |
| #14 search (#11 OR #12 OR #13) | 5,793 |
| #15 MeSH descriptor: [Colles’ Fractures] this term only | 86 |
| #16 MeSH descriptor: [Hip Fractures] explode all trees | 1,269 |
| #17 MeSH descriptor: [spinal Fractures] this term only | 717 |
| #18 MeSH descriptor: [Fractures, Bone] this term only | 1,329 |
| #19 MeSH descriptor: [Lumbar Vertebrae] this term only | 2,469 |
| #20 search (#15 OR #16 OR #17 OR #18 OR #19) | 5,466 |
| #21 search (#10 AND #14 AND #20) Publication year from 2014 to 2016, in Trials | 58 |
